Therapeutic Thursdays: It’s ok to not be ok: Ketamine and esketamine for treatment resistant depression (C.E.)
Major Depressive Disorder (MDD) is common psychiatric condition that causes significant disability and disease burden. Treatment for this condition may require multiple medication trials. Up to thirty percent of individuals with MDD do not receive adequate benefit from several antidepressant drug trials and are considered treatment resistant. The management of treatment resistant depression (TRD) often requires novel approaches. One such approach is to use N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine or esketamine. This session will review the use of ketamine and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.